CAJ | 학술논문

目的：探讨尤瑞克林联合依达拉奉治疗急性大面积脑梗死的临床疗效及安全性。方法180例急性大面积脑梗死患者随机分为对照组、治疗A组、治疗B组，每组各60例，3组均给予抗血小板聚集，脱水降颅内压、他汀、神经营养剂，根据病情调整血压、血糖、防治并发症等常规治疗，治疗A组在常规对照组基础上加用依达拉奉，治疗B组在治疗A组基础上联合尤瑞克林，3组疗程14 d。于治疗前和治疗后14 d监测3组C反应蛋白（CRP）的变化，治疗前和治疗后14、90 d对3组患者进行神经功能缺损（NIHSS）评分、日常生活能力（Barthel指数评分）评定，并评估90 d的临床疗效，记录不良反应。结果治疗14 d后治疗B组CRP降低较治疗A组及对照组明显（P＜0.05），治疗B组14 d、90 d神经功能缺损程度、90 d日常生活能力及临床疗效均优于治疗A组及对照组（P＜0.05），不良反应未明显增加。结论尤瑞克林联合依达拉奉治疗急性大面积脑梗死安全、有效。
목적：탐토우서극림연합의체랍봉치료급성대면적뇌경사적림상료효급안전성。방법180례급성대면적뇌경사환자수궤분위대조조、치료A조、치료B조，매조각60례，3조균급여항혈소판취집，탈수강로내압、타정、신경영양제，근거병정조정혈압、혈당、방치병발증등상규치료，치료A조재상규대조조기출상가용의체랍봉，치료B조재치료A조기출상연합우서극림，3조료정14 d。우치료전화치료후14 d감측3조C반응단백（CRP）적변화，치료전화치료후14、90 d대3조환자진행신경공능결손（NIHSS）평분、일상생활능력（Barthel지수평분）평정，병평고90 d적림상료효，기록불량반응。결과치료14 d후치료B조CRP강저교치료A조급대조조명현（P＜0.05），치료B조14 d、90 d신경공능결손정도、90 d일상생활능력급림상료효균우우치료A조급대조조（P＜0.05），불량반응미명현증가。결론우서극림연합의체랍봉치료급성대면적뇌경사안전、유효。
Objective To observe the effect and safety of urinarykallid combined with edaravone in treating acute massive cerebral infarction(AMCI). Methods 180 patients with AMCI were randomly divided into 3 groups:control group(n=60) , treatment group A(n=60) and treatment group B(n=60). Besides a basic 14‐day therapy ,patients in treatment group A were given edaravone ,treatment group B received urinarykallid based on treatment group A. We recorded the change of CRP ,Na‐tional Institutes of Health Stroke Scale(NlHSS) scores and Barthelindex score(BI) before treatment and after 14‐and 90‐day treatment.Results After 14-day treatment ,The CRP of group B decreased more significantly than that of group A and the contol group(P<0.05);And likewise ,the lower NIHSS scores and the higher BI scores in group B (P<0.05). All groups had no severe adverse events in the whole period. Conclusion Urinarykallid combined with edaravone in the treatment of acute massive cerebral infarction were proved to be effective and safe.